August 7, 2025Phathom Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.79 EPS, expectations were ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Prucalopride Tablets, 1 mg and 2 mg (USRLD: Motegrity Tablets, 1 mg and 2 mg).

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Ahmedabad: Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets ...

Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...

Pharmexcil Chairman warns US tariffs on Indian pharma will impact global industry, affecting affordable healthcare and ...

Zydus Lifesciences has secured a no objection certificate from Health Canada for its ZDS-Varenicline tablets, designed to aid ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Zydus Lifesciences receives NOC for Varenicline tablets to aid in smoking cessation, with annual sales of CAD 15 million.